Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term

Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term

Abstract Seizures in patients with developmental and epileptic encephalopathies (DEEs) are often highly resistant to various antiseizure medications. Perampanel (PER) is a novel antiseizure medication that non-competitively inhibits the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor a...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirokazu Yamagishi, Hitoshi Osaka, Kazuhiro Muramatsu, Karin Kojima, Yukifumi Monden, Tadahiro Mitani, Yuta Asakura, Keizo Wakae, Kohei Nagai, Toshihiro Tajima
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Reports
Subjects:
Perampanel
Lennox-Gastaut syndrome
Epilepsy with myoclonic atonic seizures
Long-term
Efficacy & safety
Online Access:https://doi.org/10.1038/s41598-024-82014-5
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Seizures in patients with developmental and epileptic encephalopathies (DEEs) are often highly resistant to various antiseizure medications. Perampanel (PER) is a novel antiseizure medication that non-competitively inhibits the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and is expected to reduce seizure frequency not only for focal seizures and generalized tonic-clonic seizures (GTCS) but also for other seizure types. This study aimed to clarify the long-term therapeutic efficacy and tolerability of PER in patients with DEEs. We analyzed data regarding patients’ background characteristics, medication retention, trends in seizure frequency, and adverse events obtained from 24 patients with DEEs who had been on PER treatment for 60 months. The retention rates were 62.5% and 46.9% at 12 and 60 months, respectively. At 60 months after PER initiation, the rate of patients with > 50% seizure reduction was 33.3%, 33.3%, 38.5%, 54.5%, 54.5%, and 36.4% among patients with atypical absence seizures, tonic seizures, focal seizures, GTCS, myoclonic seizures, and atonic seizures, respectively. The frequency of adverse events was 70.8%. PER showed long-term efficacy in various seizure types. PER is a promising treatment option for patients with DEEs.
ISSN:2045-2322

Similar Items